The dispute arose when ABT said it was reluctant to launch and commercialize DM-1796, an investigational, once-daily formulation of gabapentin for the management of post-herpetic neuralgia.
Shares of DepoMed (DEPO) dropped as much as 13.37% to $5.70 in pre-market trading as the company tries to resolve its ongoing dispute with Abbott Laboratories (ABT) over the commercialization of its investigational drug DM-1796. T
